Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Nivolumab Plus Brachytherapy/ADT Improves Disease Control in Grade Group 5 Prostate Cancer

May 10th 2023

John Michael "JM" Bryant, MD, expands on the results of the interim analysis of the single-center, single-arm phase 2 trial for patients with grade group 5 prostate cancer treated with the combination of nivolumab and standard of care.

Novel Treatment Modalities in Metastatic Hormone-Sensitive Prostate Cancer

May 10th 2023

Closing out their segment on metastatic hormone-sensitive prostate cancer, panelists review other treatment modalities being investigated in clinical trials.

Educating Patients on Treatment Options in Metastatic HSPC

May 10th 2023

Expert insight on methods to educate patients on available treatment options in the setting of metastatic hormone-sensitive prostate cancer.

Short-term QOL Scores Lower in Non-Hispanic Black Patients With Prostate Cancer After Radical Prostatectomy

May 9th 2023

Mara Koelker, MD, discusses the rationale of evaluating racial differences in QOL for patients with prostate cancer and ways to address these short-term disparities in a real-world setting.

Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPC

May 8th 2023

Drs Manning and Armstrong discuss the impact of lesion size and symptomatic status of bone metastases on radiotherapy selection in mCRPC, highlighting ongoing trials and emerging data.

Closing Thoughts on the Future of mCRPC Treatment

May 8th 2023

Matthew Manning, MD, and Andrew Armstrong, MD, discuss the remaining unmet needs in mCRPC, clinical trials and novel agents to look out for, and share practical advice for other clinicians treating patients with the disease.

Dr Cole on Race-Based Differences in Prostate Cancer–Specific Mortality

May 5th 2023

Alexander Putnam Cole, MD, discusses findings from a study investigating the effect of type of definitive treatment on race-based differences in prostate cancer–specific mortality in patients with prostate cancer.

Limited Drug Antagonism Between Darolutamide and Docetaxel Confirms Efficacy and Tolerability of ARASENS Triplet in mHSPC

May 5th 2023

Bertrand F. Tombal, MD, PhD, explains how data on the clinically relevant drug-drug interactions and TRAEs with darolutamide, docetaxel and ADT support previously reported efficacy data from the ARASENS trial, and presents lingering questions and caveats from this trial that should be addressed through continued research.

Dr Sieber on Comorbidities and the Risk of Cardiovascular Events in Prostate Cancer

May 4th 2023

Paul Sieber, MD, discusses the importance of assessing risk factors for cardiovascular events in patients with prostate cancer who are initiating androgen deprivation therapy.

Dr Jones on Clinical Fracture Incidence in mHSPC

May 3rd 2023

Craig Jones, MBChB, discusses findings from an analysis of fracture incidence in patients with metastatic hormone-sensitive prostate cancer from the phase 2/3 STAMPEDE trial platform protocol.

Metastatic Hormone-Sensitive Prostate Cancer: Data from TITAN and PEACE-1

May 3rd 2023

Key opinion leaders reflect on data from the TITAN and PEACE-1 clinical trials, respectively, in the setting of metastatic hormone-sensitive prostate cancer.

Metastatic Hormone-Sensitive Prostate Cancer: Data From ENZAMET and ARCHES

May 3rd 2023

Shared insight on the ENZAMET and ARCHES clinical trials, which utilized combination enzalutamide strategies in patients with metastatic hormone-sensitive prostate cancer.

Apalutamide Plus ADT Improves PSA PFS in Biochemically Relapsed Prostate Cancer

May 2nd 2023

Apalutamide plus androgen deprivation therapy with or without abiraterone acetate and prednisone improved prostate-specific antigen progression-free survival in patients with biochemically relapsed prostate cancer, according to long-term follow-up data from the phase 3 PRESTO trial.

Patient Profile: A 67-Year-Old Man with mCRPC and Asymptomatic Bone Metastases

May 1st 2023

Centering discussion on a patient profile of mCRPC with asymptomatic bone metastases, experts share best approaches to treating and optimizing outcomes for such patients, including supplement recommendations to prevent bone fractures.

Safety and Efficacy Data on Radium-223 for the Palliative Treatment of mCRPC

May 1st 2023

Drs Armstrong and Manning review the safety and efficacy data from the ALSYMPCA trial of radium-223 in patients with mCRPC.

Considerations for Treatment Selection for Patients with Disease Progression on Radium-223

May 1st 2023

A medical oncologist and radiation oncologist share clinical insight on how they might approach subsequent treatment selection in patients with mCRPC who have disease progression on or after radium-223.

Patient Profile: A 72-Year-Old Man with mCRPC and Multiple Bone Metastases

May 1st 2023

Radiation oncologist Matthew Manning, MD, shares the patient profile of a 72-year-old man with mCRPC receiving palliative treatment with radium-223.

Dr Lowentritt on PSA Response and Time to Castration Resistance in mCSPC

April 29th 2023

Benjamin H. Lowentritt, MD, FACS, discusses prostate-specific antigen response and time to castration resistance in patients with metastatic castration-sensitive prostate cancer started on apalutamide, enzalutamide, or abiraterone acetate.

Enzalutamide With or Without Leuprolide Offers MFS Benefit Vs Leuprolide Alone in nmHSPC With High-risk BCR

April 29th 2023

Treatment with the androgen receptor inhibitor enzalutamide plus leuprolide led to a significant reduction in the risk of metastasis or death compared with placebo plus leuprolide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

Apalutamide Demonstrates Robust Real-World Effectiveness in mCSPC

April 29th 2023

Patients with metastatic castration-sensitive prostate cancer treated with the androgen receptor–signaling inhibitor apalutamide achieved prostate-specific antigen responses that trended higher and rates of progression to castration resistance that trended lower than those receiving enzalutamide or abiraterone acetate/